Literature DB >> 12957697

Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity.

Sven Hänsel1, Grit Lässig, Frank Pistrosch, Jens Passauer.   

Abstract

OBJECTIVE: Cardiovascular mortality is excessive in patients with rheumatoid arthritis (RA). It has been proposed that the chronic inflammatory state of RA contributes to accelerated atherosclerosis. The aim of this study was to determine whether endothelial dysfunction, an early sign of arteriosclerosis, is present in young, long-term RA patients receiving standard methotrexate (MTX) therapy. Furthermore, we tested whether etanercept (ENC), a TNF-alpha receptor blocker, resulted in improved endothelial function compared to MTX in the same patients.
METHODS: We studied eight RA patients twice: (1) on MTX and (2) after MTX washout and receiving ENC. Eight healthy volunteers matching for age, gender, height, weight and conventional cardiovascular risk factors served as control (C). All participants received intrabrachial infusions of increasing doses of acetylcholine (ACh, endothelium-dependent vasodilator) and glyceryl-trinitrate (GTN, endothelium-independent vasodilator). Forearm blood flow (FBF) was measured by bilateral venous occlusion plethysmography.
RESULTS: Disease activity of RA was comparably low during both MTX and ENC (DAS 28 3.9+/-0.3 and 3.5+/-0.3). FBF in response to ACh was reduced in RA compared to C (P<0.01). Switching from MTX to ENC failed to improve vascular responsiveness to ACh. GTN comparably increased FBF in all groups.
CONCLUSIONS: Our study for the first time demonstrates that long-term RA is associated with manifested endothelial dysfunction. Switching from MTX to ENC in stable RA patients has no beneficial effect on endothelial function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957697     DOI: 10.1016/s0021-9150(03)00281-8

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  26 in total

1.  Autoantibodies and thrombophilia in RA: TNFalpha and TNFalpha blockers.

Authors:  G F Ferraccioli; E Gremese
Journal:  Ann Rheum Dis       Date:  2004-03-17       Impact factor: 19.103

2.  Cardiovascular injury in systemic autoimmune diseases: an update.

Authors:  Maurizio Turiel; Piercarlo Sarzi-Puttini; Fabiola Atzeni; Vito De Gennaro Colonna; Luigi Gianturco; Livio Tomasoni
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

3.  Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis.

Authors:  William Bilsborough; Helen Keen; Andrew Taylor; Gerard J O'Driscoll; Leonard Arnolda; Daniel J Green
Journal:  Rheumatol Int       Date:  2006-06-24       Impact factor: 2.631

4.  Risk of coronary artery disease in patients with ankylosing spondylitis: a systematic review and meta-analysis.

Authors:  Patompong Ungprasert; Narat Srivali; Wonngarm Kittanamongkolchai
Journal:  Ann Transl Med       Date:  2015-03

Review 5.  The role of endothelial function and its assessment in rheumatoid arthritis.

Authors:  Faisel Khan; Bernat Galarraga; Jill J F Belch
Journal:  Nat Rev Rheumatol       Date:  2010-03-30       Impact factor: 20.543

6.  Change of the aortic elasticity in rheumatoid arthritis: Relationship to associated cardiovascular risk factors.

Authors:  Hamdy Sliem; Gamela Nasr
Journal:  J Cardiovasc Dis Res       Date:  2010-07

7.  Lower limb arterial incompressibility and obstruction in rheumatoid arthritis.

Authors:  I del Rincón; R W Haas; S Pogosian; A Escalante
Journal:  Ann Rheum Dis       Date:  2004-07-22       Impact factor: 19.103

8.  Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis.

Authors:  A Ferrante; A R Giardina; F Ciccia; G Parrinello; G Licata; G Avellone; E Giardina; R Impastato; Giovanni Triolo
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

Review 9.  Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Patompong Ungprasert; Narat Srivali; Ittikorn Spanuchart; Charat Thongprayoon; Eric L Knight
Journal:  Clin Rheumatol       Date:  2014-01-15       Impact factor: 2.980

Review 10.  Targeting vascular (endothelial) dysfunction.

Authors:  Andreas Daiber; Sebastian Steven; Alina Weber; Vladimir V Shuvaev; Vladimir R Muzykantov; Ismail Laher; Huige Li; Santiago Lamas; Thomas Münzel
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.